Second Victory for Aurobindo Pharma: USFDA approves its Azithromycin
It’s a good day or Aurobindo Pharma today. The USFDA has not only approved its Parkinson's disease treatment drug Entacapone, but also given its final approval to make and market its antibiotic of Azithromycin. The approval for Azithromycin comes for an injection of 500mg per vial, which is generic equivalent of Pfizer's Zithromax injection, an antibacterial drug indicated for the treatment...
Login or Register to read the full article
It’s a good day or Aurobindo Pharma today. The USFDA has not only approved its Parkinson's disease treatment drug Entacapone, but also given its final approval to make and market its antibiotic of Azithromycin.
The approval for Azithromycin comes for an injection of 500mg per vial, which is generic equivalent of Pfizer's Zithromax injection, an antibacterial drug indicated for the treatment of patients with community-acquired pneumonia and pelvic inflammatory disease, the company said.
The approval for Azithromycin comes for an injection of 500mg per vial, which is generic equivalent of Pfizer's Zithromax injection, an antibacterial drug indicated for the treatment of patients with community-acquired pneumonia and pelvic inflammatory disease, the company said.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd